The JAK2 V617F mutation in patients with cerebral venous thrombosis
- 1 June 2012
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 10 (6), 998-1003
- https://doi.org/10.1111/j.1538-7836.2012.04719.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Advances in Understanding and Management of Myeloproliferative NeoplasmsCA: A Cancer Journal for Clinicians, 2009
- The JAK2V617F mutation and thrombosisBritish Journal of Haematology, 2008
- The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorderThrombosis and Haemostasis, 2008
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disordersJournal of Thrombosis and Haemostasis, 2007
- Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settingsJournal of Medical Genetics, 2007
- The Myeloproliferative DisordersThe New England Journal of Medicine, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemiaAnnals of Hematology, 1999
- Budd-chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseasesJournal of Molecular Medicine, 1989